ArticleImmunology and cell biology2017

CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.

Ekua W Brenu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.